ATE540671T1 - Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien - Google Patents

Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien

Info

Publication number
ATE540671T1
ATE540671T1 AT04744149T AT04744149T ATE540671T1 AT E540671 T1 ATE540671 T1 AT E540671T1 AT 04744149 T AT04744149 T AT 04744149T AT 04744149 T AT04744149 T AT 04744149T AT E540671 T1 ATE540671 T1 AT E540671T1
Authority
AT
Austria
Prior art keywords
lipophilic microphase
pharmaceutical compositions
forming materials
amorphous drug
adsorbates
Prior art date
Application number
AT04744149T
Other languages
English (en)
Inventor
Walter Christian Babcock
Dwayne Thomas Friesen
Ravi Mysore Shanker
Daniel Tod Smithey
Original Assignee
Bend Res Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bend Res Inc filed Critical Bend Res Inc
Application granted granted Critical
Publication of ATE540671T1 publication Critical patent/ATE540671T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04744149T 2003-08-04 2004-07-23 Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien ATE540671T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49241003P 2003-08-04 2003-08-04
PCT/IB2004/002498 WO2005011635A2 (en) 2003-08-04 2004-07-23 Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials

Publications (1)

Publication Number Publication Date
ATE540671T1 true ATE540671T1 (de) 2012-01-15

Family

ID=34115618

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04744149T ATE540671T1 (de) 2003-08-04 2004-07-23 Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien

Country Status (8)

Country Link
US (2) US9023393B2 (de)
EP (1) EP1653927B1 (de)
JP (1) JP2007501218A (de)
AT (1) ATE540671T1 (de)
BR (1) BRPI0413277A (de)
CA (1) CA2532931A1 (de)
MX (1) MXPA06001417A (de)
WO (1) WO2005011635A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
EP2548894A1 (de) * 2005-02-03 2013-01-23 Bend Research, Inc. Pharmazeutische Zusammensetzungen mit erhöhter Leistung
DE602006012310D1 (de) * 2005-05-26 2010-04-01 Flamma Spa An titandioxidnanopartikeln absorbierte pharmazeutische wirkstoffe enthaltende pharmazeutische formulierungen
EP1923053A1 (de) 2006-09-27 2008-05-21 Novartis AG Pharmazeutische Zusammensetzung umfassend Nilotinib oder dessen Salz
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
US9724362B2 (en) * 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2072042A1 (de) * 2007-12-21 2009-06-24 Lek Pharmaceuticals D.D. Aktive pharmazeutische Zutat auf einem festen Träger, amorph und mit verbesserter Löslichkeit
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
US20110142554A1 (en) * 2008-08-22 2011-06-16 Robert Terzini Container for use in pneumatic transport system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP2238979A1 (de) * 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Auf einem festen Träger adsorbierter pharmazeutischer Wirkstoff
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
EP3773509B1 (de) 2018-04-06 2023-11-01 Capsugel Belgium NV Sprühtrocknungsverfahren für teilchen mit niedrigem aspektverhältnis mit poly[(methyl-methacrylat)-co-(methacrylsäure)]
EP3824296A4 (de) 2018-07-20 2022-04-27 Lipocine Inc. Lebererkrankung
CN109901213B (zh) * 2019-03-05 2022-06-07 中国辐射防护研究院 一种基于Reuter网格的γ扫描方案生成方法及系统
MX2023003556A (es) 2020-09-29 2023-06-13 Shenzhen Pharmacin Co Ltd Composiciones farmaceuticas.
TW202345842A (zh) 2022-03-25 2023-12-01 大陸商深圳市藥欣生物科技有限公司 Ｐｒｏｔａｃ化合物之醫藥組合物及其用途

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
JPS57142911A (en) * 1981-02-28 1982-09-03 Furointo Sangyo Kk Absorption-improving agent
DE3485000D1 (de) * 1983-06-28 1991-10-10 Takeda Chemical Industries Ltd Gemahlene mischung.
US4581232A (en) * 1983-07-20 1986-04-08 Warner-Lambert Company Magnesium trisilicate suitable for preparation of medicament adsorbates
GB8413191D0 (en) * 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
US4711774A (en) * 1986-03-27 1987-12-08 Warner-Lambert Company Medicament adsorbates with complex magnesium aluminum silicate and their preparation
US4716033A (en) * 1986-03-27 1987-12-29 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
US4717565A (en) * 1986-03-27 1988-01-05 Warner-Lambert Company Process for the preparation of medicament adsorbates
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4835186A (en) * 1987-06-15 1989-05-30 American Home Products Corporation Spray dried ibuprofen
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
JP2792862B2 (ja) 1988-07-30 1998-09-03 寛治 高田 経口腸溶製剤
SE8803935L (sv) 1988-10-31 1990-05-01 Kabivitrum Ab Laekemedelskomposition
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IE60458B1 (en) 1989-10-26 1994-07-13 Elan Corp Plc Enhanced bioavailability adsorbates
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
FR2679467B1 (fr) * 1991-07-26 1993-10-15 Oreal Dispersion solide d'au moins un alcool polyhydrique dans un milieu anhydre et procede de preparation.
WO1993011749A1 (en) * 1991-12-18 1993-06-24 Warner-Lambert Company A process for the preparation of a solid dispersion
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
AU4198793A (en) * 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
JP3140465B2 (ja) * 1992-09-18 2001-03-05 山之内製薬株式会社 ハイドロゲル徐放性製剤
US6312704B1 (en) * 1993-09-30 2001-11-06 Gattefosse, S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
JPH07291854A (ja) 1994-04-26 1995-11-07 Tanabe Seiyaku Co Ltd 溶解性の改善された医薬品製剤
AU4314196A (en) 1994-12-21 1996-07-10 Yamanouchi Pharmaceutical Co., Ltd. Solid composition with improved solubility and absorbability
US5626878A (en) * 1995-01-10 1997-05-06 Warner Lambert Company Reduction of electrostatic forces between magnesium trisilicate adsorbates
SI9500059A (sl) 1995-02-23 1996-08-31 Lek Tovarna Farmacevtskih Postopek za pripravo trdnih površinskih disperzij amorfnih, v vodnih medijih slabo topnih učinkovin in njihova uporaba
JPH08291854A (ja) 1995-04-20 1996-11-05 Zexel Corp 車両用差動装置
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
ES2199289T3 (es) * 1995-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Dispersion solida de derivados de xantina.
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
DE19610932A1 (de) * 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
CN1226282A (zh) 1996-06-28 1999-08-18 诺沃挪第克公司 具有齿斑葡聚糖酶活性的重组酶
DE19627430A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19627431A1 (de) * 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6207671B1 (en) * 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
TW426516B (en) 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
DE19704243A1 (de) 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
DE19704244A1 (de) * 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
WO1999027946A1 (en) 1997-12-02 1999-06-10 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
AU745687B2 (en) 1997-02-26 2002-03-28 Pfizer Inc. Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-alpha binding to its CCR1 receptor
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
CN1112927C (zh) 1997-07-29 2003-07-02 法玛西雅厄普约翰美国公司 自体乳化剂形式的酸性亲脂性化合物的药物组合物
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
HN1998000115A (es) 1997-08-21 1999-06-02 Warner Lambert Co Formas de dosificación farmacéuticas sólidas
WO1999014204A1 (en) 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741051A1 (de) 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741400A1 (de) 1997-09-19 1999-03-25 Bayer Ag Benzyl-biphenyle
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
FR2772271B1 (fr) * 1997-12-11 2000-09-01 Union Pharma Scient Appl Nouvelle association pharmaceutique a activite analgesique
EA003137B1 (ru) 1998-02-05 2003-02-27 Пфайзер Продактс Инк Новые производные дигидроксигексановой кислоты
WO1999041237A1 (en) 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6191162B1 (en) * 1998-05-28 2001-02-20 Medical Research Institute Method of reducing serum glucose levels
US20010025046A1 (en) 1999-06-24 2001-09-27 Rong(Ron) Liu Self-emulsifying systems containing anticancer medicament
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
JP2000016934A (ja) * 1998-06-30 2000-01-18 Eisai Co Ltd テプレノンを含有した錠剤
EP2127642A3 (de) * 1998-08-13 2010-02-24 Cima Labs, Inc. Mikroemulsionen als feste Dosisformen zur oralen Verabreichung
US6376481B2 (en) * 1998-09-02 2002-04-23 Mcneil-Ppc, Inc. Sterol esters in tableted solid dosage forms
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
CA2345103C (en) 1998-09-25 2011-04-26 Monsanto Company (r)-chiral halogenated 1-substitutedamino-(n+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
EP1115694A1 (de) 1998-09-25 2001-07-18 Monsanto Company Substituierte n-aliphatisch- n-aromatisch tertiäre heteroalkylamine für die hemmung der aktivität des cholesteryl-ester-transfer-proteins
AU2157400A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
EP1027885B1 (de) 1999-02-09 2008-07-09 Pfizer Products Inc. Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
ATE404178T1 (de) 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
DE60039379D1 (de) 1999-02-10 2008-08-21 Pfizer Prod Inc Pharmazeutische feste Dispersionen
JP2000236076A (ja) * 1999-02-15 2000-08-29 Nec Corp 半導体装置及びその製造方法
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
GB9920558D0 (en) 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
ES2299441T3 (es) 1999-12-08 2008-06-01 Pharmacia Corporation Forma en estado solido de celecoxib con biodisponibilidad potenciada.
KR100694667B1 (ko) 1999-12-08 2007-03-14 동아제약주식회사 생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
MXPA02006335A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
PT1242055E (pt) 1999-12-23 2008-07-02 Pfizer Prod Inc Forma de dosagem de fármaco baseada em hidrogel
BR0016555A (pt) * 1999-12-23 2002-09-17 Pfizer Prod Inc Composições farmacêuticas que proporcionam concentrações acrescidas de droga
CA2396640A1 (en) 2000-01-28 2001-08-02 Smithkline Beecham Corporation Electrospun pharmaceutical compositions
JP2001316248A (ja) * 2000-02-28 2001-11-13 Eisai Co Ltd 油状薬物含有組成物の製造方法
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
AR027656A1 (es) * 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
AU2001268338A1 (en) 2000-06-12 2001-12-24 Smith Kline Beecham Corporation Novel solid dispersion compositions
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6602523B1 (en) * 2000-08-17 2003-08-05 Technology Holding, Llc. Composite material and process for increasing bioavailability and activity of a beneficial agent
HUP0400263A2 (hu) * 2001-06-21 2005-03-29 Pfizer Products Inc. Koleszteril-észter transzfer protein inhibitort tartalmazó önemulgeáló készítmény
CZ20033456A3 (en) * 2001-06-22 2004-07-14 Pfizer Products Inc. Pharmaceutical compositions comprising adsorbates of amorphous drug
KR100425226B1 (ko) 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
US6796586B2 (en) 2001-07-09 2004-09-28 Twin Bay Medical, Inc. Barb clamp
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
JP2005509001A (ja) * 2001-10-29 2005-04-07 セリクス， インコーポレイテッド 投薬形態の三次元懸濁液プリンティング
JP2005523262A (ja) * 2002-02-01 2005-08-04 ファイザー・プロダクツ・インク 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物

Also Published As

Publication number Publication date
BRPI0413277A (pt) 2006-10-10
EP1653927B1 (de) 2012-01-11
US20050031693A1 (en) 2005-02-10
CA2532931A1 (en) 2005-02-10
EP1653927A2 (de) 2006-05-10
MXPA06001417A (es) 2006-05-15
WO2005011635A3 (en) 2005-03-17
USRE47033E1 (en) 2018-09-11
WO2005011635A2 (en) 2005-02-10
US9023393B2 (en) 2015-05-05
JP2007501218A (ja) 2007-01-25

Similar Documents

Publication Publication Date Title
ATE540671T1 (de) Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
DE60320940D1 (de) Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
ATE486586T1 (de) Pharmazeutische zusammensetzungen, enthaltend adsorbate eines arzneimittels in amorpher form
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
AP2002002552A0 (en) Pharmaceutical compositions providing enhanced drug concentrations.
IL179250A0 (en) Stable crystal of 4-oxoquinoline compound and pharmaceutical compositions containing the same
IL184758A0 (en) New pharmaceutical compositions useful in the transmucosal administration of drugs
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
DE602005015229D1 (de) Medizinische artikel mit aus verschmolzenen polymerpartikeln gebildeten wirkstoffhaltigen bereichen
EP1613334A4 (de) Alkoholfreie transdermale insulin-zusammensetzung und verfahren zu ihrer herstellung und verwendung
EE05082B1 (et) Pürroolirea ühend, selle valmistamine ja kasutamine lipiidi- ja kolesteroolitaset alandava ravimi valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
SV2008002612A (es) Forma de dosificacion de liberacion retardada oral altamente biodisponibles de succionado de o-desmetilvanlafaxina ref. am101721salvo
GB2431346C (en) A combination composition comprising paracetamol and ibuprofen
GB0523576D0 (en) Drug composition and its use in therapy
ATE348619T1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
ATE301463T1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
ATE467412T1 (de) Pharmazeutische zusammensetzung in form eines hydrogels zur transdermalen verabreichung von wirkstoffen
DE602005016055D1 (de) Feste pharmazeutische Arzneimittelformulierung enthaltend Diacerein und Meloxicam
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases
NO20064123L (no) Farmasoytisk blanding av [+]-erytro-meflokin og dens anvendelse
GB0423008D0 (en) Organic compounds
DOP2003000571A (es) Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas
EP1941928A4 (de) Elektrodenstruktur für iontophorese zur verabreichung eines in einem nanoteilchen eingeschlossenen arzneimittels und diese verwendende iontophorese-vorrichtung
HK1105875A (en) Pharmaceutical compositions useful in the transmucosal administration of drugs